Ultralife (ULBI) Earnings Date & Reports

Key Takeaways

• Ultralife reported second-quarter 2026 revenue of $47.9 million, down 1.3% from $48.6 million a year earlier.
• GAAP earnings per share (EPS, or profit allocated to each outstanding share) tripled to $0.15, up from $0.05 in the prior-year quarter.
• Gross margin expanded 500 basis points to 28.9%, helped by favorable product mix and a one-time tariff refund.
• Backlog reached a company record of $117.5 million, up 39% year over year, and grew further to nearly $130 million by July.
• Communications Systems revenue surged 39.3%, while the larger Battery & Energy segment slipped 3.7%.
• Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, adjusted for one-time items) rose 49.5% to $6.1 million.

Earnings Context and Why It Matters

Ultralife Corporation is a global supplier of power solutions and communication systems serving government, defense, and commercial customers. Its second-quarter report marked a pivotal moment for investors, as the company returned to stronger profitability after a challenging start to 2026. The prior quarter delivered a modest net loss driven by production disruptions and one-time costs, so this quarter's profit rebound and margin expansion were closely watched signals that management's operational turnaround efforts were taking hold. With defense modernization spending and growing demand for advanced battery technologies in the broader market, Ultralife's results offered a timely read on both internal execution and the health of its core end markets.

Reported Results

Ultralife reported second-quarter 2026 revenue of $47.9 million, a 1.3% decline from $48.6 million in the same period last year. Net income attributable to the company rose to $2.5 million, or $0.15 per diluted share on a GAAP basis (Generally Accepted Accounting Principles, the standard framework for reporting), compared with $0.9 million, or $0.05 per share, a year earlier.

Gross profit increased 19.5% to $13.9 million, with gross margin expanding 500 basis points to 28.9% from 23.9%. The improvement reflected favorable product mix across both segments and a $1.1 million net refund of IEEPA tariffs (import tariffs tied to the International Emergency Economic Powers Act), which contributed 230 basis points to the margin gain. Excluding that refund, consolidated gross margin was 26.6%. Operating income climbed 52.3% to $3.4 million, and operating margin widened to 7.2% from 4.6%.

Adjusted EBITDA rose 49.5% to $6.1 million, or 12.8% of sales, up from $4.1 million, or 8.5% of sales, a year earlier. Management did not provide specific revenue or EPS guidance but maintained an outlook for profitable growth in 2026.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Ultralife and its industry peers, the AI Screener offers a practical way to surface relevant opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

Investors responded favorably to the quarter, with ULBI shares jumping roughly 19% on the day of the report. Since reporting, the stock has gained about 34.6%, outperforming the S&P 500 over the same period, as the market rewarded the profit rebound, margin expansion, and record backlog.

Sentiment was tempered somewhat by the composition of the margin improvement. A meaningful portion of the gain stemmed from the one-time tariff refund rather than recurring operational improvements. Still, investors appeared encouraged by management's progress on scrap reduction, supply-chain fixes, and new-product commercialization, viewing the results as evidence that the company's turnaround is gaining traction despite soft commercial demand in oil and gas.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Ultralife can convert its record backlog into sustained revenue growth. Management indicated that July order activity pushed backlog to nearly $130 million, suggesting continued demand momentum heading into the second half of 2026.

Margin durability will be a central theme. The company expects two supply-chain and scrap-reduction initiatives to generate roughly $600,000 to $800,000 in annual gross-margin savings, and lean manufacturing projects are underway at its Raynham facility. Investors will be watching for those benefits to materialize without the support of one-time tariff refunds.

Product commercialization also remains a key catalyst. New offerings in communications, including ruggedized computing and amplifier products, along with conformal wearable batteries and Electrochem-cell-based drone applications, are expected to move into production through late 2026 and into 2027. Continued recovery in Communications Systems and stabilization in the Battery & Energy segment will be important indicators of whether Ultralife can deliver on its goal of profitable growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations